Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adeel Siddiqui

Internal Medicine Raleigh, NC Medical Doctor

NPI 1609812338 CMS profile 978720

3521 Haworth Dr, Raleigh, NC 27609

Open in the dashboard

General payments

$3,478

182 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adeel Siddiqui of Raleigh, NC is reported in the CMS Open Payments database as having received $3,478 across 182 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $453 23
2024 General $463 25
2023 General $701 33
2022 General $433 24
2021 General $469 34
2020 General $328 20
2019 General $631 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adeel Siddiqui
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Adeel Siddiqui were reported at $453. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Adeel Siddiqui Internal Medicine median Middle half National median
2019 $631 $159 $48–$570 $163
2020 $328 $119 $33–$402 $114
2021 $469 $135 $37–$521 $132
2022 $433 $141 $42–$496 $149
2023 $701 $149 $45–$519 $160
2024 $463 $154 $47–$537 $164
2025 $453 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $378 23 payments
  2. Novo Nordisk Inc $349 20 payments
  3. Amgen Inc. $294 19 payments
  4. Medtronic Vascular, Inc. $284 3 payments
  5. AstraZeneca Pharmaceuticals LP $259 16 payments
  6. Pfizer Inc. $136 8 payments
  7. Lilly USA, LLC $133 8 payments
  8. Philips Electronics North America Corporation $113 1 payment
  9. Boston Scientific Corporation $108 2 payments
  10. GlaxoSmithKline, LLC. $103 7 payments
  11. Other $1,321 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,308 179 payments
  2. Education $170 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $247 14 payments
  2. RYBELSUS $218 12 payments
  3. UBRELVY $215 13 payments
  4. Repatha $170 11 payments
  5. FARXIGA $152 10 payments
  6. Integrity $140 1 payment
  7. QULIPTA $122 6 payments
  8. (6574) Coronary Other $113 1 payment
  9. Otezla $110 7 payments
  10. AIMOVIG $94 6 payments
  11. Other $2,757 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 123 drugs

Part D claims

6,404

Median for Internal Medicine: 777

Drug cost

$430,744

Median for Internal Medicine: $73,373

Branded share of claims

19.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 73 $79,832
Ozempic Semaglutide Brand 56 $67,968
Jardiance Empagliflozin Brand 47 $40,206
Rybelsus Semaglutide Brand 16 $34,770
Januvia Sitagliptin Phosphate Brand 41 $32,689
Mounjaro Tirzepatide Brand 17 $19,909
Myrbetriq Mirabegron Brand 18 $15,340
Synthroid Levothyroxine Sodium Brand 132 $12,391
Xarelto Rivaroxaban Brand 13 $9,192
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 20 $9,039

The 10 drugs with the highest cost, of 123 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$105,990

Of which drugs: $15,071

Medicare patients

338

Average age 76

Services billed

1,740

146 women, 192 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 43%
Ischemic heart disease 28%
Chronic kidney disease 23%
Diabetes 22%
Atrial fibrillation 21%
Depression 21%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 12 12 $3,477
Vaccine for influenza for injection into muscle 90653 Office 38 38 $3,076
Sarscv2 vac 30mcg trs-suc im 91320 Office 14 14 $2,115

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $31
$31 — —
Veozah
  • Astellas Pharma US Inc $31
$31 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $29
$29 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $21
$21 — —
Wegovy
  • Novo Nordisk Inc $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

182 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record